Chinook Therapeutics Inc.

Chinook Therapeutics Inc.

World Rank (Jan-05-2024)
3,888
Market Cap (Jan-05-2024)
3.500 Billion USD
World Rank (Jul-30-2023)
4,787
Market Cap (Jul-30-2023)
2.609 Billion USD
World Rank (Jan-07-2022)
10,625
Market Cap (Jan-07-2022)
0.807 Billion USD
Headquarters Country
USA
Employee Count
214
Employee Count as of Date
As on 2022
Headquarters City/State
Washington
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
6 Million USD
Annual Operating Income in USD
-173 Million USD
Annual Net Income in USD
-187 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
574 Million USD
Total Liabilities in USD
132 Million USD
Total Equity in USD
441 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
CHINOOK THERAPEUTICS, INC.
Company Profile

Chinook Therapeutics, Inc. is a Clinical Stage Biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. The headquarters is in USA.

Novartis acquired Chinook Therapeutics Inc. for 3.5 billion USD in 2023.

Chinook’s pipeline includes two late-stage assets in clinical development to treat Immunoglobulin A Nephropathy (IgAN), atrasentan and zigakibart (BION-1301), as well as earlier stage research and development programs. Atrasentan, an oral endothelin A receptor antagonist (ERA) currently in Phase 3 development for IgAN with a pivotal readout expected in Q4 2023, has shown significant reductions in proteinuria.

Facts About Company

Chinook Therapeutics, Inc. Annual Total Revenue for year ending Dec-2022 was 6 million USD and and Net loss for year ending Dec-2022 was -187 million USD.

Chinook Therapeutics, Inc. Annual Total Revenue for year ending Dec-2021 was 51 million USD and and Net loss for year ending Dec-2021 was -102 million USD.

As on 2022, Chinook Therapeutics, Inc. has 214 employees.

Share